by Scott Harwood | Sep 26, 2022
Mariana C. Castells MD, PhD, Division of Allergy and Clinical Immunology, Brigham and Women’s Hospital, and Professor of Medicine, Harvard Medical School, discusses the results of TouchStone, a patient and healthcare provider (HCP) survey focused on...
by Scott Harwood | Aug 30, 2022
The U.S. Food and Drug Administration (FDA) has approved pemigatinib for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. Pemigatinib is a selective fibroblast growth factor receptor (FGFR) inhibitor and is the...
by Scott Harwood | Aug 25, 2022
Bruce Cree, MD, PhD, MAS, Associate Professor of Clinical Neurology in the Department of Neurology at the University of California San Francisco, discusses the common issue of delay in getting orphan drugs covered by health insurance companies. As many in the...
by Scott Harwood | Mar 21, 2022
The U.S. Food and Drug Administration (FDA) has approved ganaxolone for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder, a rare form of genetic epilepsy, in patients two years of age and older. Ganaxolone is a...
by Scott Harwood | May 10, 2021
Bruce Cree, MD, PhD, MAS, Associate Professor of Clinical Neurology in the Department of Neurology at the University of California San Francisco, discusses two-year data from the open-label extension of the N-MOmentum trial (NCT02200770) of inebilizumab, an...
